Advisory
Committee for Pharmaceutical Science
Pharmacology
Toxicology Subcommittee Meeting
Topic # 1 Overview of Toxicogenomics at the Drug Development and Regulatory
Interface
Lesko, LJ, et al Pharmacogenetics and pharmacogenomics in drug
development and regulatory decision making: report of the first
FDA-PWG-PhRMA-DruSafe Workshop. J Clin Pharmacol 43(4): 342-58, 2003
Woodcock, J., Drug development and regulation in the
age of pharmacogenomics, Presentation to the FDA
Science Board.
Topic # 2 Toxicogenomic Data Quality and Database Issues
Petricoin, EF III et al. Medical applications of microarray
technologies: A regulatory science perspective. Nature
Genetics. supplement 2002; 32:474-479.
Topic # 3 CDER FDA Product Review and Linking Toxicogenomics Data with Toxicology
Outcome
Brazma, A. et al., Minimum information about a microarray
experiment (MIAME) - toward standards for microarray data. Nature Genetics
2001; 29:365-371.
CDER Guidance for Industry. Content and Format of Investigational New
Drug Applications (INDs) for Phase 1 Studies of Drugs, Including
Well-Characterized, Therapeutic, Biotechnology-Derived Products. November 1995.